This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
== Epidemiology == Biliary atresia seems to affect females slightly more often than males, and Asians and African Americans more often than Caucasians. It is common for only one child in a pair of twins or within the same family to have the condition. There seems to be no link to medications or immunizations given immediately before or during pregnancy. Diabetes during pregnancy particularly during the first trimester seems to predispose to a number of distinct congenital abnormalities in the infant such as sacral agenesis, transposition of the great vessels and the syndromic form of biliary atresia.
== Active site and catalytic mechanism == All the proteolytic activity of the asparagine peptide lyases is only self-cleavages, then no further peptidase activity occurs. The main residue of the active site is the asparagine and there are other residues involved in the catalytic mechanism, which are different between the different families of asparagine peptide lyases. The cleavage mechanism consists in the cyclization of the asparagine, assisted by other active site residues. In certain conditions, the asparagine cyclic structure nucleophilically attacks its C-terminal peptide bond to the main chain forming a new bond to create a stable succinimide, cleaving itself from the main chain and consequently releasing the two halves of the product.
In the case of bleeding on probing, which is a diagnostic tool for dentists to routinely check the condition of the gums, the periodontal probe, when inserted gently into the gingival sulcus, is used to measure the depth of the periodontal pocket but upon contact with the sulcular epithelium, should not cause bleeding in individuals with good gingival health. This is due to the resiliency of the sulcular epithelium that has a healthy thickness with a strong underlying collagen architecture. Sites with greater inflammation tend to have more cells yet possess a weaker collagen architecture, making bleeding on probing more noticeable, which is a common finding in stage 2 (early) gingivitis. This highlights the importance of the sulcular epithelium as a physical barrier to protect the underlying connective tissue. When its surface is ulcerated and discontinuous, it allows bacteria to enter more easily. In fact, the total area where bacteria can come in contact with the affected gum tissue is estimated to be as large as the palm of an adult’s hand. Once in the established lesion stage of gingivitis, collagen depletion continues as more polymorphonuclear (PMN) cells seep into the gingival sulcus and infiltrate the spaces within the sulcular epithelium. Permeability of the gingival sulcus (sulcular epithelium & junctional epithelium) also increases with the progress of gingival inflammation.
=== Casting === Brec Bassinger was cast as Courtney Whitmore / Stargirl in September 2018. Johns called the casting of Stargirl a difficult process, auditioning hundreds of actresses for the role. On why Bassinger was perfect for the role, Johns said: "Immediately... I knew she was Courtney. She has the humor, she has the enthusiasm, the energy, the innate optimism, and Brec really embodies who Stargirl is". The following roles were cast in November: Anjelika Washington as Beth Chapel / Doctor Mid-Nite, Yvette Monreal as Yolanda Montez / Wildcat, and Christopher James Baker as Henry King / Brainwave. In January 2019, Luke Wilson was cast as Pat Dugan / S.T.R.I.P.E. Amy Smart joined the cast as Barbara Whitmore in February, along with Neil Jackson as Jordan Mahkent / Icicle, Trae Romano as Mike Dugan, Hunter Sansone as Cameron, and Cameron Gellman as Rick Tyler / Hourman. Also Jake Austin Walker was cast as Henry King Jr. and Meg DeLacy cast as Cindy Burman. The following members of the Justice Society of America were cast in December 2018: Joel McHale as Sylvester Pemberton / Starman, Lou Ferrigno Jr. as Rex Tyler / Hourman, Brian Stapf as Ted Grant / Wildcat, and Henry Thomas as Charles McNider / Doctor Mid-Nite. As well, Joy Osmanski was cast as Paula Brooks / Tigress, Neil Hopkins was cast as Lawrence "Crusher" Crock / Sportsmaster, and Nelson Lee was cast as Dr. Ito / Dragon King, members of the Injustice Society. In April 2019, Hina Khan was cast as Anaya Bowin.
Sources: en.wikipedia.org
== Prognosis == The prognosis for individuals with Pompe disease varies according to the onset and severity of symptoms, along with lifestyle factors. Without treatment the infantile form (which can typically be predicted by mutation analysis) of the disease is particularly lethal — in these cases, the time taken to begin treatment is critical, with evidence that days (not weeks or months) matter. Myozyme (alglucosidase alfa) is a recombinant form of the human enzyme acid alpha-glucosidase, and is also currently being used to replace the missing enzyme. In a study which included the largest cohort of patients with Pompe disease treated with enzyme replacement therapy (ERT) to date findings showed that Myozyme treatment clearly prolongs ventilator-free survival and overall survival in patients with infantile-onset Pompe disease as compared to an untreated historical control population. Furthermore, the study demonstrated that initiation of ERT before six months of age, which could be facilitated by newborn screening, shows great promise to reduce the mortality and disability associated with this devastating disorder. Taiwan and several states in the United States have started newborn screening and results of such regimens in early diagnosis and early initiation of the therapy have dramatically improved the outcome of the disease; many of these babies have reached normal motor developmental milestones.
=== Pakistan === On 8 April, amidst the deadline set by Trump, Pakistani Prime Minister Shehbaz Sharif called on Trump to extend his deadline for Iran to reopen the Strait of Hormuz by two weeks. It was also reported by CBS, quoting Pakistani sources, that a ceasefire with Iran was being negotiated by Sharif. Later that day, Prime Minister Sharif announced on social media that "...Islamic Republic of Iran and the United States of America, along with their allies, have agreed to an immediate ceasefire everywhere including Lebanon and elsewhere, EFFECTIVE IMMEDIATELY..." while also lauding both parties for their diplomacy. In a 10 April social media post, Pakistani Defense Minister Khawaja Asif called Israel "evil and a curse for humanity" while accusing Israel of genocide against Lebanon. The Israeli Prime Minister's Office responded, "This is not a statement that can be tolerated from any government, especially not from one that claims to be a neutral arbiter for peace". Asif later deleted the post.
English blood (Old English blod) derives from Germanic and has cognates with a similar range of meanings in all other Germanic languages (e.g. German Blut, Swedish blod, Gothic blōþ). There is no accepted Indo-European etymology.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.